Zealand Pharma's Petrelintide Shows Double-Digit Weight Loss in Phase 2 Trial
Event summary
- Zealand Pharma's Phase 2 ZUPREME-1 trial for petrelintide showed up to 10.7% body weight reduction vs. 1.7% for placebo.
- Gastrointestinal adverse events were mild and comparable to placebo, with no vomiting or treatment discontinuations at the maximally effective dose.
- Petrelintide improved cardiometabolic risk factors, including reductions in waist circumference, high-sensitivity C-reactive protein, and triglycerides.
- Results published in The Lancet Diabetes & Endocrinology and presented at EASD 2026.
- Global Phase 3 ZUPREME registrational program for petrelintide monotherapy initiated.
The big picture
Zealand Pharma's positive Phase 2 data for petrelintide comes amid intense competition in the weight management space, where tolerability and durability of effect are key differentiators. The collaboration with Roche, a global pharmaceutical leader, underscores the strategic importance of petrelintide in addressing the growing obesity epidemic. The initiation of Phase 3 trials marks a critical step in validating petrelintide's potential as a long-term treatment option.
What we're watching
- Clinical Efficacy
- Whether petrelintide's double-digit weight loss and tolerability profile can be sustained in Phase 3 trials.
- Regulatory Pathway
- The pace at which Zealand Pharma advances petrelintide through the global Phase 3 program.
- Commercial Strategy
- How Zealand Pharma and Roche plan to position petrelintide in the competitive weight management market.
Related topics